Led by Dr. Nicole Ezer, a team of RI-MUHC researchers have initiated a clinical trial of ciclesonide to possibly prevent mild cases of COVID-19 from worsening.
Ciclesonide is an inhaled and nasal steroid drug currently used for asthma and nasal rhinitis. Laboratory studies have already shown that treatment with ciclesonide can decrease viral replication of SARS-Cov2, the virus responsible for the disease. This placebo-controlled randomized trial will confirm if the administration of inhaled and nasal ciclesonide can reduce the severity of respiratory symptoms among mild cases of COVID-19 and potentially avoid the need for hospitalization and oxygen.
Diagnosed with COVID? Contain COVID at the source. Protect your lungs! Register for a clinical trial of inhaled ciclesonide:
To learn more about the study:
please visit contain-covid19.com or email Info@contain-covid19.com
“We know the COVID-19 virus starts by multiplying in the nose and progresses downwards to the lower parts of the airways and lungs. We hope that targeting the site of viral replication with inhaled and nasal ciclesonide will reduce early viral replication and decrease severity of COVID-19 illness,”– Nicole Ezer
- Nicole Ezer, Respirologist, MD, MPH
- James Martin, Respirologist, MD, Dsc
- Todd Lee, Infectious Diseases, MD Msc
- Emily Macdonald, Internal Medicine, MD, Msc
- Susan Bartlett, Clinical Psychologist, Senior Scientist
- Andrea Benedetti, Epidemiology and Biostatistics PHD
- Annie-Claude Jalbert, MD
- Rola Hamed, MsC
- Ankita Ghatak, MSc Candidate
- Ben Smith, Respirologist, MD, Msc